Editorial
Iron infusions: balancing benefits and harms
- Aust Prescr 2026;49:209-11
- 1 December 2026
- DOI: 10.18773/austprescr.2026.047
anaemia, ferric carboxymaltose, ferric derisomaltose, intravenous iron, iron deficiency, iron polymaltose, iron sucrose
Aust Prescr 2026;49:209-11
https://doi.org/10.18773/austprescr.2026.047
Iron deficiency anaemia (IDA) is the most common anaemia in Australia.1 Intravenous iron supplementation represents a major advance in the therapeutic options for managing iron deficiency and it has become increasingly popular as first-line management. However, the convenience of rapid replacement of iron stores using an iron infusion always needs to be weighed against possible harm to the patient.
Intravenous infusion of iron bypasses the normal regulatory mechanism controlling iron absorption. Mistakes in dosing are difficult to correct. Adverse reactions to intravenous iron (e.g. hypophosphataemia) can occur and occasionally can be challenging to manage. Confusion between the anaemia of chronic disease and IDA is possible and can lead to inappropriate therapy.
There are several intravenous iron preparations available in Australia (Table 1).2 All intravenous iron preparations are nanoparticle solutions with iron atoms bound to carbohydrate chains. Once injected into the bloodstream, the nanoparticles are taken up by macrophages, the carbohydrate chains are catabolised to simple sugars, and the iron is transported by transferrin to tissues and stored in ferritin.3
Table 1 Intravenous iron products approved in Australia2
| Generic name | Brand name | Maximum iron dose and infusion rate [NB1] |
|
Ferric carboxymaltose |
Ferinject |
1000 mg over 15 minutes |
|
Ferric derisomaltose [NB2] |
Monofer |
1500 mg over 30 minutes |
|
Iron polymaltose |
Ferrosig |
2500 mg over 4 hours |
|
Iron sucrose |
Venofer |
1000 mg over 6 hours |
| NB1: Smaller doses can be given more rapidly. Refer to product information, local protocols or the Australian Injectable Drugs Handbook2 for administration instructions and precautions. NB2: Ferric derisomaltose is also known as iron isomaltoside. | ||
The introduction to the Pharmaceutical Benefits Scheme (PBS) in 2014 of ferric carboxymaltose, which allows a rapid infusion, was followed by a marked increase in the number of iron infusions administered in Australia. Previously, the long duration of an iron infusion made administration outside of a hospital setting largely impractical. In 2013, there were approximately 67,000 PBS prescriptions for iron infusions (iron polymaltose and iron sucrose).4 In the 2024–2025 financial year, the PBS subsidised more than 550,000 prescriptions for ferric carboxymaltose at a total cost of approximately A$150 million, excluding infusion costs;5 these data do not include other intravenous iron preparations or doses delivered in hospital that were not subsidised by the PBS.
The reasons for this large increase in the number of iron infusions are multiple and include:
Infusion of iron compounds is not without risks. Allergic reactions, including anaphylaxis, can occur with all iron compounds, but are rare.7 Complement activation–related pseudoallergy reactions (CARPA, or Fishbane reactions) are more common and vary directly with infusion speed. These reactions are an acute but non–life-threatening combination of symptoms typically characterised by transient flushing and tightness or pain in the chest and back. The reactions resolve spontaneously with cessation of the infusion and usually do not recur on rechallenge.8,9 Ferric derisomaltose is reported to have a higher incidence of infusion reactions than ferric carboxymaltose.10
All intravenous iron preparations can elevate circulating fibroblast growth factor-23 (FGF-23), which, in some patients, leads to hypophosphataemia. Hypophosphataemia is usually asymptomatic and resolves spontaneously,11 but it can be severe and difficult to treat. In this issue of Australian Prescriber, Ludington et al.12 report a case of severe prolonged hypophosphataemia following a dose of iron polymaltose in a patient who had previously experienced hypophosphataemia after receiving ferric carboxymaltose. Ferric carboxymaltose has the highest risk of symptomatic hypophosphataemia of the intravenous iron preparations.13 Baseline phosphate concentration should be measured in patients who require multiple high-dose iron infusions or have other risk factors for hypophosphataemia (e.g. hyperparathyroidism, malnutrition),14 and careful consideration should be given to the selection of the iron compound for infusion.
Oral iron remains the recommended first-line therapy for uncomplicated iron deficiency and IDA, because the risks of serious harm from oral therapy are significantly lower than those of intravenous therapy. Those who will respond reliably to oral therapy will show an increase in their haemoglobin concentration of at least 1 g/dL within 14 days.15 Oral therapy needs to continue for approximately 3 to 6 months to replenish iron stores. It may be associated with adverse effects, including abdominal pain and constipation. The direct financial cost to the patient of oral therapy for correction of iron deficiency may exceed that for intravenous therapy. Patients should be made aware of the benefits and risks of oral and intravenous iron and should be involved in decisions regarding the route of administration.Intramuscular iron injections are painful, can produce permanent skin and tissue staining and are not recommended.
Intravenous iron therapy should be confined to patients with intolerance to oral therapy, impaired iron absorption from medical or surgical causes or where blood loss exceeds the oral iron absorptive capacity. Dosing should be based on current guidelines and approved product information, and tailored to the individual. For those taking bone antiresorptive medication, particularly denosumab, and in whom intravenous iron supplementation is unavoidable, additional monitoring and consideration of the timing of iron administration is advisable because of the increased risk of severe hypocalcaemia and hypophosphataemia.16 Patients with previous serious reactions should be managed with appropriate consultant physician advice in a setting where close monitoring is available. Avoidance of permanent skin staining from extravasation requires a faultless infusion technique.17
The extraordinary growth in intravenous iron prescriptions reflects advances in treatment options for a common condition. However, the use of intravenous iron is not without risks and costs. As expenditure and utilisation continue to rise, the focus should shift to stewardship. The challenge lies in ensuring that the increasing use of intravenous iron is matched by appropriateness. Prescribers need to be confident in their ability to differentiate IDA from other anaemias and should carefully consider the route of iron replacement to avoid unnecessary infusions. BloodSafe Australia provides resources and an online training course on the diagnosis and management of IDA.18
This article was finalised on 8 October 2026.
Conflicts of interest: Hugh Dickson has received funding from Recce Pharmaceuticals for a study of a topical anti-infective therapy.
Jayanthi Ramanathan has received support from Amgen, CSL, Novartis and Sanofi for travel and accommodation for conference attendance within Australia. Jayanthi Ramanathan is a member of the Australian Prescriber Editorial Advisory Committee; he was excluded from editorial decisions related to the acceptance and publication of this editorial.
This article is peer reviewed.
Australian Prescriber welcomes Feedback.
Chief Adviser, Strategy and Alliance, South Western Sydney Local Health District, Sydney
Honorary Medical Officer, Department of Ambulatory Care, Liverpool Hospital, Sydney
Adjunct Professor, UNSW, Sydney
Senior Staff Specialist, Hospital in the Home Service, Liverpool Hospital, Sydney
Staff Specialist, Institute of Precision Medicine and Bioinformatics, Royal Prince Alfred Hospital, Sydney
Senior Lecturer, School of Medicine, Western Sydney University